Next-generation point-of-care testing in pediatric human immunodeficiency virus infection facilitates diagnosis and monitoring of treatment.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
08 Jul 2022
08 Jul 2022
Historique:
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
12
7
2022
Statut:
epublish
Résumé
Point-of-care (PoC) testing facilitates early infant diagnosis (EID) and treatment initiation, which improves outcome. We present a field evaluation of a new PoC test (Cepheid Xpert® HIV-1 Qual XC RUO) to determine whether this test improves EID and assists the management of children living with human immunodeficiency virus (HIV) infection. We compared 2 PoC tests with the standard-of-care (SoC) test used to detect HIV infection from dry blood spots in newborn infants at high risk of in utero infection. We also evaluated the ability of the PoC tests to detect HIV total nucleic acid (TNA) in children living with HIV infection who had maintained undetectable plasma viremia following very early combination antiretroviral therapy (cART) initiation. Qualitative (Qual) detection of HIV using the Xpert® HIV-1 Qual XC RUO ("RUO") and Xpert® HIV-1 Qual ("Qual") PoC tests was compared in 224 infants with the SoC DBS Roche COBAS® HIV-1/HIV-2 qualitative test. The same 2 PoC tests were also evaluated in 35 older children who had initiated cART before 21 days of age and maintained undetectable plasma viremia for a mean of 25 months. No discrepancies were observed in detection of HIV infection via the 2 PoC tests or the SoC test in the 224 neonates studied, but only 95% of the SoC test results were generated compared with 100% of the PoC test results (P = .0009). The cycle threshold values for the research use only (RUO) assay were the lowest of the 3 assays (P < .0001 in each case). In 6 of the 35 early-treated aviremic children, HIV TNA was detected by RUO but not Qual. The RUO assay outperforms Qual in detecting HIV-1 infection. RUO would therefore potentially improve EID and assist in identifying cART-adherent early-treated children with the lowest HIV TNA levels and the highest HIV cure potential.
Identifiants
pubmed: 35801794
doi: 10.1097/MD.0000000000029228
pii: 00005792-202207080-00065
pmc: PMC9259159
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29228Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Mofenson L, Cohn J, Sacks E. Challenges in the early infant diagnosis and treatment cascade. J Acquired Immune Defic Syndr. 2020;84(Suppl 1):S1–4.
Tachnau K-G, Kuhn L, Coovadia A, et al. Xpert® HIV-1 Point of Care Test for neonatal diagnosis in the birth testing programme of a maternity hospital—a field evaluation study. Lancet HIV. 2017;4:e442–8.
Sabi I, Mahiga H, Mgaya J, et al. Accuracy and operational characteristics of Xpert human immunodeficiency virus point-of-care testing at birth and until week 6 in HIV-exposed neonates in Tanzania. Clin Infec Dis. 2019;68:615–22.
Bianchi F, Cohn J, Sacks E, et al.; EGPAF POC EID Study Team. Evaluation of a routine point-of-care intervention for early infant diagnosis of HIV: an observational study in eight African countries. Lancet HIV. 2019;6:e373–81.
Millar JR, Bengu N, Fillis R, et al. High-frequency failure of combination antiretroviral therapy in paediatric HIV infection is associated with unmet maternal non-adherence. EClinicalMedicine. 2020;22:1003441003344.
Republic of South Africa National Department of Health. Guideline for the prevention of mother to child transmission of communicable infections. Published 2019. Available at: https://www.knowledgehub.org.za/system/files/elibdownloads/2019-10/PMTCT .
Available at: https://www.cepheid.com/en/tests/Virology/Xpert-HIV-1-Qual . Accessed 17 August 2021.
Available at: https://diagnostics.roche.com/gb/en/products/params/cobas-hiv-1-hiv-2-qualitative-test.html . Accessed 17 August 2021.
Millar JR, Mvo Z, Bengu N, et al. Increasing diagnostic uncertainties in children with in utero HIV infection. Ped Infec Dis J. 2019;38:e166–8.
Shearer WT, Rosenblatt HM, Gelman RS, et al.; Pediatric AIDS Clinical Trials Group. Lymphocyte subsets in healthy children from birth through 18 years of age: the pediatric AIDS clinical trials group P1009 study. J Allergy Clin Immunol. 2003;112:973–980.
Lugada ES, Mermin J, Kaharuza F, et al. Downing, population-based 327 hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol. 2004;11:29–34.
Millar J, Bengu N, Vieira VA, et al. Early initiation of ART following in utero HIV infection is associated with low viral reservoirs but other factors determine subsequent plasma viral rebound. J Infec Dis. 2021;224:1925–1934.
Veldsman KA, Laughton B, Janse van Rensburg A, et al. Viral suppression is associated with HIV-antibody level and HIV-1 DNA detectability in early treated children at 2 years of age. AIDS. 2021;35:1247–52.
Luzuriaga K, Tabak B, Garber M, et al. HIV Type (HIV) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. J Infec Dis. 2014;210;1529–38.
Shiau S, Abrams EJ, Arpadi SM, et al. Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission? Lancet HIV. 2018;5:e250–8.
Goulder P, Lewin SR, Leitman EM. Paediatric HIV infection: the potential for cure. Nat Rev Immunol. 2016;16:259–71.